Table 2.

Relative increase in median antibody titers (%) between day 0 and 21–22 months; relative reduction in median antibody titers during day 28 and 21–22 months, to poliovirus types 1–3, by study group with 95% confidence intervals calculated using bootstrapping with 10,000 replications.

		Day 0 and 21–22 months comparison		Day 28 and 21–22 months comparison
Median % relative increase (95% CI)	p-Value	Median % relative reduction (95% CI)	p-Value
Type 1	Salk IPV	1121.3 (896.4–2126.5)	Ref	92.1 (84.2–92.9)	Ref
Sabin IPV	1028.5 (535.1–1714.3)	0.534	92.1 (90.0–93.7)	0.543
aSabin IPV	893.0 (151.4–1904.2)	0.399	87.4 (80.1–92.1)	0.613
Type 2	Salk IPV	458.7 (147.3–1032.1)	Ref	96.0 (92.9–96.8)	Ref
Sabin IPV	694.7 (124.4–1305.0)	0.705	95.0 (93.7–96.0)	0.655
aSabin IPV	402.8 (100.0–893.0)	0.945	95.0 (93.7–96.8)	0.933
Type 3	Salk IPV	1043.9 (685.8–1670.5)	Ref	93.7 (91.0–95.5)	Ref
Sabin IPV	1276.9 (250.1–2727.8)	0.892	92.1 (91.0–95.0)	0.665
aSabin IPV	1150.0 (694.7–2396.5)	0.768	93.7 (92.1–96.8)	0.500

Note: excluded 1 subject missing data for 21–22 months.